Artificial intelligence has greatly impacted the drug discovery pipeline by achieving human-like performance in the field of retrosynthesis [1]}. Retrosynthesis is the task of breaking down a chemical compound recursively into molecular precursors until a set of commercially available building block molecules is found [1]}, [3]}. Consequently, the goal is to provide a valid synthesis route for a molecule. Potential applications of these synthesis routes are suggestions for medical chemists on how to produce a molecule of interest [4]}, a foundation for autonomous chemistry [5]}, and using synthesizability as part of De Novo Drug Design [6]}.
